RU2228176C2 - Method for treating mastitis in cows - Google Patents

Abstract

FIELD: veterinary science. SUBSTANCE: one should intracisternally inject 1%- aqueous dioxidine solution twice daily at 12-h-long interval for 3 d. Moreover, after applying dioxidine one should additionally introduce mixoferon intramuscularly - 15 doses for the first day during the day and 25 doses - for the second day, moreover, on the 3d d it should be introduced once against 95 doses per therapy course. EFFECT: higher efficiency of therapy. 2 ex, 2 tbl

Description

The invention relates to veterinary medicine, in particular to methods for treating mastitis in cows.

Known methods of treating mastitis in cows with the use of antimicrobial agents, for example mastisan A (1), mastisan E (2). The main disadvantage of these antibiotic-containing preparations is the rapid development of resistant races of microorganisms, inhibition of the body's defense mechanisms, and the appearance of mastitis of mycotic etiology.

As a prototype, a method was selected based on the use for the treatment of mastitis in cows with a 1% aqueous solution of dioxidine, a drug of a new class of chemicals (3).

To test the effectiveness of the application of the known method for the treatment of patients with sero-catarrhal mastitis of lactating cows, 8 patients of lactating cows of red-motley breed were selected. Animals were in the same conditions of keeping and feeding. The diet is balanced in terms of basic nutritional components, animals used an active exercise. The diagnosis of mastitis was made on the basis of a clinical examination of the body of the cows, in which the main attention was paid to the condition of the mammary gland, and a laboratory study of the secretion from the affected lobes of the udder (reaction with a 2% solution of mastidine). The animals were treated with 1% dioxidine solution according to the instructions for its use.

First, a glass bottle was heated with a 1% solution of dioxidine with a volume of 100 cm ³ in warm (40 ° C) water for 15 minutes. Then, using a sterile needle and a 20-gram syringe, 20 cm ^{3 of a} 1% solution of dioxidine were collected from the vial. After milking the cow and carefully removing the pathological secretion from the sore udder, the nipple tip was disinfected with 70% ethanol, the syringe cannula was placed at the external opening of the nipple canal, and a 1% solution of dioxidine was introduced into the nipple cavity by pressing the syringe plunger. With a light massage of the nipple of the udder, the drug was displaced from the bottom up into the nipple part of the milk tank. The introduction of a 1% solution in a dose of 20 cm ³ was carried out twice a day with an interval of 12 hours 3-4 days in a row.

For the animals during the experiment conducted daily clinical observations. The treatment results were evaluated on the 7th and 10th day after the last injection of the drug comprehensively taking into account the clinical examination of cows and laboratory studies of the secretion of the cured udder lobes. The data of the studies are presented in table 1. After 5 injections of dioxidine, 2 cows recovered, 6 administrations - 3 animals, 7 and more - 3 cows. On average, 6.1 injections of a 1% aqueous solution of dioxidine were required to recover 1 cow suffering from serous-catarrhal mastitis during lactation.

The main disadvantage of this method is the low therapeutic efficacy, which cannot be increased by increasing its concentration, since the solubility limit of dioxidine in water at room temperature is 1%. An increase in the volume of intracisternally administered 1% dioxidine causes irritation of the epithelium of the mammary gland. Another disadvantage is the need for multiple injections of the drug into the udder tank (6 or more times) per treatment course, which increases the labor costs of veterinarians and negatively affects the condition of the mucous membrane of the nipple canal and the mammary gland tank.

The invention solves the problem of increasing the therapeutic efficacy of antimicrobial agents for mastitis in cows.

The technical result from the use of the invention is to reduce the number of medical procedures and the timing of recovery.

This is achieved by the fact that in the method of treating mastitis in cows, including the introduction of intracisternally 1% aqueous solution of dioxidine twice a day with an interval of 12 hours for 3 days, additionally after dioxidine, mixoferon is administered intramuscularly 15 doses for the first time during the day and 25 doses - the second, while on the 3rd day it is administered once at the rate of 95 doses per treatment course.

The essence of the invention lies in the fact that in conjunction with an antibacterial chemotherapeutic drug, the biologically active drug mixoferon is used, which is a mixture of leukocyte interferon proteins that have the ability to stimulate immune processes and the activity of immunocompetent cells, as well as increase the non-specific resistance of animals.

Mixoferon is a homogeneous powder, well soluble in distilled water, it is released in glass ampoules or vials of 5, 10, 20, 50 or 100 doses each. Mixoferon is introduced in the form of a sterile solution prepared at the rate of 1 dose in 1 ml, which corresponds to 100 thousand ME of total antiviral activity. It is known that mixoferon is used for prophylactic and therapeutic purposes in gastrointestinal and acute respiratory diseases of viral and bacterial etiology in adult animals and their young (4).

The use of mixoferon in the treatment of mastitis in cows is not known.

It has been experimentally established that in the treatment of mastitis in cows with a 1% aqueous solution of dioxidine according to instruction (3), additional intramuscular administration of mixoferon at the rate of 95 doses per treatment course, in which 15 doses are administered first time per day and 25 doses, the second, are reduced the number of treatment procedures and the timing of recovery.

Examples of the method.

Example 1

The method was studied in the treatment of serous-catarrhal mastitis in lactating cows and was tested on 10 cows. Animals were in the same conditions of keeping and feeding. The diet is balanced in basic nutrients, animals used an active exercise. The diagnosis of mastitis was made on the basis of a clinical examination of the animal’s body and a laboratory study of the secretion from the affected udder lobes (reaction with a 2% mastidine solution).

Cows for 3 days twice a day with an interval of 12 hours were first injected intracisternally with 20.0 cm ^{3 of a} 1% aqueous solution of dioxidine, and then additionally mixed doses of 15 doses of mixoferon for the first time during the day and 25 doses for the second. On the 3rd day, the drugs were administered once, while mixoferon in the amount of 15 doses and the course of treatment was completed. Doses of mixoferon according to paragraph 3.2 of the instructions for use (4) were dissolved in distilled water at the rate of 1 dose in 1 cm ³ , which corresponds to 100 thousand ME of total antiviral activity. The total amount of mixoferon administered was 95 doses in the form of 95 cm ^{3 of a} sterile solution.

Used mixoferon, packaged in glass bottles of 20 doses. To dissolve mixopheron used distilled water in an amount of 20 cm ³ per contents of one bottle. After dissolving the drug in 1 cm ³ contained 1 dose of mixoferon, which corresponds to 100 thousand ME total antiviral activity.

For the animals during the experiment conducted daily clinical observations. The treatment results were evaluated on the 7th and 10th days after the last injection of the drugs comprehensively taking into account the clinical examination of cows and laboratory studies of milk of the cured udder lobes.

Table 1 presents the comparative results of the therapeutic efficacy of treating serous-catarrhal mastitis in lactating cows by the proposed and known methods.

From the data presented it follows that in the treatment of mastitis in cows by the proposed method, the recovery time is reduced by 1.7 treatment procedures.

Example 2

The experiment was conducted on 20 lactating cows (two groups of 10 cows), patients with subclinical mastitis.

The animals in the groups were in the same conditions of keeping and feeding. The diet is balanced in terms of basic nutritional components, animals used an active exercise. The diagnosis of mastitis was made on the basis of a clinical examination of the body of cows and a laboratory study of the secretion from the affected udder lobes (reaction with a 2% mastidine solution).

Animals of one group were used only intracisternally 1% solution of dioxidine according to the instructions for use (3), as in previous experiments, heated to 40 ° C at a dose of 20 cm ³ , twice a day with an interval of 12 hours, three days in a row.

In animals of the other group, mixoferon was additionally intramuscularly administered 15 doses the first time during the day and 25 doses the second. On the 3rd day, the drugs were administered once, while mixoferon in the amount of 15 doses and the course of treatment was completed. A sterile solution of mixoferon for injection was prepared analogously to example 1.

For the animals during the experiment conducted daily clinical observations. The treatment results were evaluated on the 20th day after the last injection of the drugs comprehensively, taking into account the clinical examination of cows and laboratory studies of the secretion of the treated udder lobes.

The data of the studies are presented in table 2.

Table 2 presents the comparative results of the therapeutic effectiveness of the treatment of subclinical mastitis in lactating cows by the proposed and known methods.

From the data of table 2 it follows that the best therapeutic effect (recovered + improved condition) was achieved by the proposed method of treatment for complex use - dioxidine + mixoferon. At the same time, 80% of the animals recovered and 20% improved. At the same time, in the treatment in a known manner, consisting in the use of a 1% aqueous solution of dioxidine, 70% recovered, the condition improved in 10% and 20% of the animals remained sick.

Thus, the proposed method for the treatment of mastitis in cows is more effective than the known one.

Sources of information

1. The instruction on the use of Mastisan A for the treatment of cows with mastitis was approved by the General Veterinary Administration of the Ministry of Agriculture of the USSR on October 25, 1982 No. 115-6A.

2. The manual on the use of Mastisan E for the treatment of cows with mastitis was approved by the General Veterinary Administration of the Ministry of Agriculture of the USSR on October 22, 1982 No. 115-6A.

3. The instruction on the use of the drug "Dioxidine 1% solution" for veterinary medicine was approved by the Department of Veterinary Medicine of the Ministry of Agriculture and Food of the Russian Federation on May 26, 1999 No. 13-5-2 / 1613.

4. The instruction on the use of Mixopheron is approved by the Veterinary Department of the Ministry of Agriculture and Food of the Russian Federation dated July 24, 1998, No. 13-5-2 / 1341.

Claims (1)

A method of treating mastitis in cows, including the introduction of intracisternally 1% aqueous solution of dioxidine twice a day with an interval of 12 hours for 3 days, characterized in that in addition to dioxin, mixoferon is administered intramuscularly 15 doses for the first time during the day and 25 doses the second time, while on the 3rd day it is administered once at the rate of 95 doses per treatment course.